[
  {
    "ts": null,
    "headline": "Biogen starts dosing in Phase III trial of Friedreich ataxia therapy",
    "summary": "The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.",
    "url": "https://finnhub.io/api/news?id=e9479e4add711224ea8bea7f18235d31ab0d90d0cfbd714f3fa974dbf498ffcb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1750333100,
      "headline": "Biogen starts dosing in Phase III trial of Friedreich ataxia therapy",
      "id": 135397346,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "The trial aims to assess the safety, pharmacodynamics, efficacy, and pharmacokinetics of the therapy in nearly 255 subjects.",
      "url": "https://finnhub.io/api/news?id=e9479e4add711224ea8bea7f18235d31ab0d90d0cfbd714f3fa974dbf498ffcb"
    }
  }
]